By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


MolMed S.p.A. 

via Olgettina, 58

Milan    20132  Italy
Phone: 39-0221277-1 Fax: 39-0221277-220



Company News
MolMed S.p.A. Signs an Agreement With GlaxoSmithKline (GSK) to Develop a Production Process for a Gene Therapy 8/5/2011 11:02:55 AM
MolMed S.p.A. Release: Results of three Phase II Trials in Lung Cancer Indications Confirm Safety and Antitumour Activity of NGR-hTNF 6/3/2011 8:10:53 AM
FDA Grants Orphan Drug Designation for MolMed S.p.A.'s Investigational Antiumour Drug 8/29/2008 10:20:28 AM
MolMed S.p.A. Key Preliminary Results of Phase II Trials Presented 5/30/2008 11:27:51 AM
Immunicon Corporation (IMMC) And MolMed S.p.A. Enter Research And Laboratory Services Agreements 9/28/2006 12:12:01 PM
Takara Bio And MolMed S.p.A. Announce That Phase I/II Clinical Trial Of HSV-TK Gene Therapy Delivers Positive Results 12/15/2005 6:16:33 PM
Takara Bio , MolMed S.p.A. Conclude R&D Agreement For HIV Gene Therapy Treatment10/19/2005 5:13:13 PM
Takara Bio's Research Partner MolMed S.p.A., European Medicines Agency Begin Discussions Concerning Phase III Clinical Studies Of HSV-TK Gene Therapy10/19/2005 5:12:16 PM